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ACE = angiotensin converting enzyme; ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CAPPP = Capto-
pril Antihypertensive Prevention Project; CCB = calcium channel blockers; HOPE = Heart Outcomes Prevention Evaluation; STOP-2 = Swedish
Trial in Old Patients with Hypertension-2.
Available online http://cvm.controlled-trials.com/content/2/2/063
Introduction
The evidence base in support of the drug treatment of
hypertension is among the strongest in medicine.
Prospective, randomised clinical trials in 50,000 individu-
als have demonstrated conclusively that pharmacological
reduction of blood pressure reduces the risk of cardiovas-
cular events and all-cause mortality [1].
The magnitude of reduction in stroke events in trials is
exactly that predicted from long-term epidemiological
studies for the differences in systolic and diastolic blood
pressure achieved [1]. The reduction in the predominant
complication of hypertension in Western populations
(coronary heart disease events) is, while significant, rather
less than that expected. Deleterious metabolic effects of
diuretics that formed the basis of therapy in almost all the
trials might explain the shortfall in coronary heart disease
prevention. Other antihypertensive agents should avoid
these unwanted actions and could have advantages in
cardioprotection.
The suggestion that thiazide diuretics, at the low doses
used currently, have a detrimental influence on coronary
heart disease outcomes does not withstand careful
scrutiny [2]. Because diuretics have no known beneficial
effect on cardiovascular events independent of blood
pressure reduction, these agents are the appropriate
standard against which newer agents should be tested.
Stroke events appear to be prevented to the extent pre-
dicted by blood pressure reduction, regardless of how
this is achieved. The question of interest is whether
newer drugs are superior to diuretics in prevention of
coronary heart disease events for the same reduction in
blood pressure; that is, having benefits beyond blood
pressure control.
Beta-blockers
The first contenders were the beta-blockers. There were
great expectations in the 1980s that these drugs would
be superior to diuretics, particularly because beta-block-
ers reduce the risk of reinfarction or death in patients with
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coronary heart disease [3]. This hypothesis was tested in
a series of large-scale controlled trials [4–8]. The results
were inconclusive and, in some cases, devisive [7,8].
Newer drugs
Selective alpha-blockers, angiotensin converting enzyme
(ACE) inhibitors and calcium channel blockers (CCB),
have potential advantages over diuretics and beta-blockers
in prevention of coronary heart disease events, and advan-
tages for surrogate endpoints have been claimed. Results
of large outcome trials did not appear until 20 years after
their introduction [9–14]. The wait was hardly worthwhile.
Although no single trial detected a significant difference in
coronary heart disease events between therapy based on
newer drugs and that based on conventional agents, the
precision of comparisons in individual trials was weak with
wide 95% confidence intervals for differences. Since clini-
cally useful differences between therapies in coronary heart
disease events could not be excluded in any of the trials,
individually the trials were not informative.
Individual trials had other shortcomings that cloud their
interpretation. In the Captopril Antihypertensive Prevention
Project (CAPPP), blood pressure at randomisation and per-
sistently throughout the trial was higher in patients treated
with captopril compared with those given conventional
therapy [10]. It is almost certain that there was failure in the
randomisation procedure [15], rendering the results unreli-
able. This extends to the findings in the subset with dia-
betes mellitus, where there appeared to be an advantage of
ACE inhibition [10]. In the Swedish Trial in Old Patients with
Hypertension-2 (STOP-2) (ACE inhibitors or CCB versus
beta-blockers or diuretics [9]) and the International Nifedip-
ine GITS Study Intervention as a Goal in Hypertension
Treatment (INSIGHT) (CCB versus diuretics [12]), with-
drawal rates from randomised therapy were unacceptably
high (34–39 and 33–40%, respectively). This inevitably
leads to underestimation of differences in treatment that
would have been seen had there been full adherence to the
randomised regimens. The apparent advantage of ACE
inhibitor over CCB in STOP-2 [9] must be treated with
caution since it arose from a subset analysis.
The only information on the relative value of alpha-block-
ade in coronary heart disease prevention comes from the
prematurely discontinued arm of the Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) [14]. The primary reason was an apparent
excess risk of heart failure in doxazosin-treated patients
compared with those randomised to chlorthalidone.
However, several factors make interpretation difficult. The
diagnostic criteria for heart failure were unconvincing, on-
treatment systolic blood pressure was higher in doxazosin-
treated subjects, and the discontinuation rate was almost
twice as high in patients randomised to alpha-blockers.
The other reason for early discontinuation was futility: even
if continued, the chance of detecting an advantage of dox-
azosin over chlorthalidone-based therapy for coronary
heart disease outcomes was less than 1%. We are left,
probably for ever, with the unsatisfactory finding that
alpha-blocker therapy might be 10% better or 17% worse
than diuretic therapy for this outcome. ALLHAT has thus
also been uninformative. ALLHAT is the only study with
sufficient statistical power to assess the impact on coro-
nary heart disease separately but, if the rest of the trial is
conducted similarly to the doxazosin arm, ALLHAT may
end up as a monumental waste of effort and resources.
The Heart Outcomes Prevention Evaluation (HOPE) study
[11] merits particular mention. Although not a comparison
of a new drug against conventional therapy in hypertensive
patients, it has been interpreted as showing an advantage
of ACE inhibition beyond blood pressure control. That
active therapy (ramipril) was better than inactive therapy
(placebo) in reducing heart attacks is hardly surprising,
but the magnitude of the reduction was greater than that
predicted from epidemiological data for the small differ-
ence in blood pressure observed. The reduction in cardio-
vascular events per mmHg difference in blood pressure
was, however, no greater than that seen in other high-risk
populations, such as diabetics, treated with other forms of
antihypertensive therapy [16]. In the absence of a positive
control group, treated with another agent providing equiv-
alent blood pressure control, no definitive conclusions can
be reached. A better acronym for HOPE might be ‘HYPE’.
Meta-analyses
In the face of uncertainty from individual trials, it has
become fashionable to resort to meta-analysis. The Blood
Pressure Lowering Treatment Trialists’ Collaboration, col-
lecting data from over 30 trials, should provide adequate
power to more reliably compare different antihypertensive
regimens with respect to particular events. A recently pub-
lished preliminary analysis [17], however, has not taken
the matter of differential protection against coronary heart
disease much further forward.
Differences in cause-specific effects between active thera-
pies were of borderline significance. No differences were
detected in comparisons of ACE inhibitors and conven-
tional therapy, but this analysis was heavily dependent on
the unreliable CAPPP [10] and STOP-2 [9]. Compared
with conventional therapy, CCB-based therapy was asso-
ciated with a 13% reduction in strokes and an increase of
similar magnitude (12%) in coronary heart disease events,
with no difference between CCB types. For both out-
comes, 95% confidence intervals were wide and the sizes
of any true differences could not be determined reliably.
Direct comparison of ACE inhibitor and CCB-based thera-
pies depended on only these two trials, between which
there was significant heterogeneity and over 90% of
events were reported from STOP-2 [9]; this does notc
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provide reliable evidence of a difference between ACE
inhibitor and CCB-based regimens.
Pahor et al [18] simultaneously published a meta-analysis
that suggested a highly significant 26% excess risk of
coronary heart disease events with CCB-based therapy
compared with other treatments. This retrospective analy-
sis used data on 27,743 patients from nine trials, while the
Trialists’ review [17] was based on 23,454 patients from
six of these trials. The analysis of Pahor et al [18] had
fewer coronary heart disease events and more strokes
than that of the Trialists [17] (ratio, 0.86 versus 1.09),
emphasising differences in the populations included. Nev-
ertheless, there was no real difference between the meta-
analyses — the clinically relevant message is that there
remains uncertainty.
Both meta-analyses [17,18] had limited statistical power
to detect differences in cause-specific outcomes. There
are insufficient data to suggest that ACE inhibitors are
superior to diuretics and beta-blockers, and insufficient
power to provide a definitive comparison of the efficacy of
CCBs against that of diuretics, beta-blockers and ACE
inhibitors for coronary heart disease events. The quality of
a meta-analysis depends on the quality of the studies
included; in both of these examples, the studies included
had major shortcomings.
The pattern of events in recent trials (a relatively low pro-
portion of cardiovascular deaths and a high rate of stroke
events) is not anticipated from epidemiological data or
from trials comparing active therapy against placebo
where cardiovascular deaths and coronary heart disease
predominate [1]. The ratio of coronary heart disease to
stroke events was 3:2 in early trials [1], while in the
recent trials [9,10,12,13] the ratio was 1:1. The newer
drugs therefore appear to have been tested in an environ-
ment very different from that where the older drugs were
evaluated, and the hypothesis of a shortfall in coronary
heart disease prevention was generated.
The short duration of trials might have contributed to the
failure to detect differential effects on coronary heart
disease events. It is conceivable that blood pressure lower-
ing per se may have a particularly important role in prevent-
ing stroke that is manifested rapidly while the influence of
drug therapy on coronary heart disease may take longer to
appear. Clinical trials provide short-term answers to long-
term problems and are, in effect, surrogates for real life
where treatment is often given for a lifetime.
Conclusions
Over the years, since new drugs were introduced, expec-
tations appear to have waned. Whereas in the beginning
the new drugs were promoted as being superior to older
drugs, the objective now seems to be to suggest equiva-
lence with diuretics and beta-blockers. In the absence of
any clear overall advantage, diuretics and beta-blockers
should remain the first-step drug therapies, with newer
agents added as necessary for blood pressure control.
Uncertainties remain about the application of experience
based upon relative reduction in risk in individual popula-
tions with varying absolute risk for cause-specific out-
comes. The generalisation of results is only appropriate if
the population to be treated is similar to that studied. Data
from populations in which stroke outcomes are as
common as coronary heart disease events may not be
readily extrapolated to Western societies where coronary
heart disease predominates. For this outcome, there
appears to be little to choose between therapies.
Recent trials [16,17] have demonstrated the critical impor-
tance of rigorous control of blood pressure in reducing the
risk of cardiovascular disease. Tight control reduces coro-
nary heart disease by 19% [17] compared with less inten-
sive control, and under-reporting of events in the largest
individual trial [16] may have led to an underestimate of
the benefit. In the majority of patients, rigorous blood pres-
sure control necessitates the use of two or more antihy-
pertensive agents in combination. The beneficial effects of
additional blood pressure lowering far outweigh any pos-
tulated differential effect between drugs. The time has
come to stop worrying about which drug to prescribe and
to instead devote our energies to lowering blood pressure
using all available therapies.
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